Our Development
Strategy
To sustain our development, we plan to integrate complementary technologies
and multiply our production capacities. The recent collaboration with Althea
Technologies now allows us to propose large scale manufacturing capabilities
for phase I to III clinical trials and market production in bacterial and
yeast systems. In addition, we plan to set up a new cGMP manufacturing unit
dedicated to preclinical and clinical manufacturing in mammalian cells.
We also work at strengthening our global presence and are currently opening
an office in Boston (United States).